News Overview

New residents at our Main Campus

Julijana Stula
Our newest residents are slowly getting ready to finally move into our new Switzerland Innovation Park Basel Area Site opening in 2022, in close collaboration with our partner SENN Development. Find out more about them, and why they choose to move into our Main Campus.

T3 Pharmaceuticals

T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviors of live bacteria. The genetically engineered bacteria selectively target solid tumors, where they deliver chosen protein payloads into the cells.

Basilea Pharmaceutical AG

Basilea Pharamceutica AG is a commercial stage biopharmaceutical company, focused on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives.

HORTUS – The eco-friendly office space
Exciting things are happening next door to our Main Camps in Allschwil. SENN Development, Herzog & de Meuron, and ZPF Engineers are jointly developing an office building with approx. 10,000 m2 of usable space for environmentally conscious (tech) companies. The building sets a new standard for sustainability: It pays back the grey building energy and is already energy-positive after about 30 years. Learn more here.

You may also like

Switzerland’s densest innovation ecosystem

Located in the heart of Europe, our vibrant ecosystem provides an ideal breeding ground for cutting-edge…> Read more

Johnson & Johnson opens Innovation Hub at the Main Campus

Johnson & Johnson has opened its first J&J Innovation Hub on the European mainland at the…> Read more

Engimmune and CSEM’s proximity accelerates their collaboration to revolutionize cancer treatment

The collaboration between Engimmune Therapeutics and the Swiss Technology Innovation Center CSEM accelerates cancer screening. Their shared success…> Read more

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.